EpilepsyNCT07863310
Effects of Nurse-Led Stigma-Reduction Education in Epilepsy
A study testing Nurse-Led Stigma-Reduction-Based Epilepsy Education in people with Epilepsy, run by Muş Alparslan University at 1 site in Turkey (Türkiye).
Trial summary
This randomized controlled trial aims to evaluate the effect of a nurse-led, stigma-reduction-based epilepsy education program on perceived/internalized stigma, concealment of epilepsy, and self-management among adults with epilepsy. Participants will be randomly assigned to an intervention group or a control group. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Epilepsy
- What is being tested?
- Nurse-Led Stigma-Reduction-Based Epilepsy Education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 65 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 14 Jul 2026to 25 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- Diagnosed with epilepsy at least 6 months before enrollment
- Able to communicate and participate in the education program without a cognitive or psychiatric condition that would prevent participation
- Able to read and understand Turkish
- Willing to participate in the study
- Provides written informed consent
Who cannot join
- Presence of a severe neurological disorder other than epilepsy
- Presence of a serious psychiatric disorder
- Advanced cognitive impairment or any condition preventing effective communication
- Unable to attend the educational sessions regularly
- Major change in the treatment protocol during the study
- Incomplete completion of data collection forms
- Withdrawal from the study at any stage
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Malatya Training and Research Hospital
Malatya
Muhammed Gönültaş, Nurse, +90 551 122 14 22, muhammedgonultas@gmail.com
About this study
Official title: Effects of Nurse-Led Stigma-Reduction Education on Internalized Stigma, Illness Concealment, and Self-Management in Epilepsy: A Randomized Controlled Trial
This randomized controlled trial aims to evaluate the effect of a nurse-led, stigma-reduction-based epilepsy education program on perceived/internalized stigma, concealment of epilepsy, and self-management among adults with epilepsy.
Participants will be randomly assigned to an intervention group or a control group. The intervention group will receive a structured nurse-led education program consisting of four weekly sessions, each lasting approximately 45-60 minutes. The program will address epilepsy-related knowledge and misconceptions, stigma and self-stigma, disclosure and concealment of epilepsy, communication, medication adherence, seizure triggers, stress management, seizure diaries, and individual self-management planning. The control group will receive routine care without additional structured education during the study period.
Outcomes related to epilepsy stigma, concealment, and self-management will be assessed using validated measurement tools.
- Conditions
- Epilepsy
- Being tested
- Nurse-Led Stigma-Reduction-Based Epilepsy Education
- Keywords
- Stigma, Self-Management, Disease Concealment, Nurse-Led Education
- Medical subject headings
- Epilepsy, Social Stigma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nurse-Led Stigma-Reduction-Based Epilepsy EducationBehavioural
Participants in the intervention group will receive a structured nurse-led epilepsy education program focused on reducing stigma and supporting disease disclosure and self-management. The program will consist of four weekly sessions lasting approximately 45-60 minutes each. The sessions will address epilepsy-related knowledge and misconceptions, stigma and internalized stigma, concealment and disclosure of epilepsy, communication, medication adherence, seizure triggers, stress management, seizure diary use, and individualized self-management planning.
| Study group | Role | What they receive |
|---|---|---|
| Experimental groups | Experimental | Participants assigned to the intervention group will receive a nurse-led, stigma-reduction-based epilepsy education program in addition to routine care. The program will consist of four weekly sessions, each lasting approximately 45-60 minutes. The sessions will cover epilepsy and seizure-related information, misconceptions about epilepsy, stigma and internalized stigma, concealment and disclosure of epilepsy, effective communication, medication adherence, seizure triggers, stress management, seizure diary use, and development of an individualized self-management plan. Receives: Behavioral: Nurse-Led Stigma-Reduction-Based Epilepsy Education |
| Routine Care Control Group | No intervention | Participants assigned to the control group will receive routine clinical care during the study period and will not receive the structured nurse-led stigma-reduction-based epilepsy education program. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Epilepsy-Related Stigma
Epilepsy-related stigma will be assessed using the Epilepsy Stigma Scale. Total scores range from 25 to 100, with higher scores indicating greater epilepsy-related stigma (a worse outcome).
Measured: Baseline and immediately after completion of the 4-week intervention
Change in Concealment of Epilepsy
Concealment of epilepsy will be assessed using the Concealment of Epilepsy Scale. Total scores range from 15 to 75, with higher scores indicating greater concealment of epilepsy (a worse outcome).
Measured: Baseline and immediately after completion of the 4-week intervention
Change in Epilepsy Self-Management
Epilepsy self-management will be assessed using the Epilepsy Self-Management Scale. Total scores range from 38 to 190, with higher scores indicating more frequent use of epilepsy self-management behaviors (a better outcome).
Measured: Baseline and immediately after completion of the 4-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start14 Jul 2026
- Primary completion5 Oct 2026 (estimated)
- Study completion25 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study was conducted as a single-blind randomized controlled study with pretest-posttest
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 65 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Muş Alparslan University
- Sponsor type
- University, hospital or other
- Collaborators
- Malatya Egitim Ve Arastirma Hastanesi
- Responsible party
- Principal investigator, Cihat Demirel, Muş Alparslan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07863310
- Sponsor's protocol ID
- epilepsi stigma
- Status last verified
- Oct 2026
- First submitted
- 25 Sep 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Nurse-Led Stigma-Reduction Education on Internalized Stigma, Illness Concealment, and Self-Management in Epilepsy: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07863310
- Acronym / sponsor ID
- epilepsi stigma
- Conditions
- Epilepsy
- Keywords
- Stigma, Self-Management, Disease Concealment, Nurse-Led Education
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 65 participants (estimated)
- Lead sponsor
- Muş Alparslan UniversityUniversity, hospital or other
- Collaborators
- Malatya Egitim Ve Arastirma Hastanesi
- Study start
- 14 Jul 2026 (actual)
- Primary completion
- 5 Oct 2026 (estimated)
- Study completion
- 25 Nov 2026 (estimated)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial aims to evaluate the effect of a nurse-led, stigma-reduction-based epilepsy education program on perceived/internalized stigma, concealment of epilepsy, and self-management among adults with epilepsy.
Participants will be randomly assigned to an intervention group or a control group. The intervention group will receive a structured nurse-led education program consisting of four weekly sessions, each lasting approximately 45-60 minutes. The program will address epilepsy-related knowledge and misconceptions, stigma and self-stigma, disclosure and concealment of epilepsy, communication, medication adherence, seizure triggers, stress management, seizure diaries, and individual self-management planning. The control group will receive routine care without additional structured education during the study period.
Outcomes related to epilepsy stigma, concealment, and self-management will be assessed using validated measurement tools.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study was conducted as a single-blind randomized controlled study with pretest-posttest
| Arm | Type | Receives |
|---|---|---|
| Experimental groups | Experimental | Behavioral: Nurse-Led Stigma-Reduction-Based Epilepsy EducationParticipants assigned to the intervention group will receive a nurse-led, stigma-reduction-based epilepsy education program in addition to routine care. The program will consist of four weekly sessions, each lasting approximately 45-60 minutes. The sessions will cover epilepsy and seizure-related information, misconceptions about epilepsy, stigma and internalized stigma, concealment and disclosure of epilepsy, effective communication, medication adherence, seizure triggers, stress management, seizure diary use, and development of an individualized self-management plan. |
| Routine Care Control Group | No intervention | –Participants assigned to the control group will receive routine clinical care during the study period and will not receive the structured nurse-led stigma-reduction-based epilepsy education program. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 years or older
- Diagnosed with epilepsy at least 6 months before enrollment
- Able to communicate and participate in the education program without a cognitive or psychiatric condition that would prevent participation
- Able to read and understand Turkish
- Willing to participate in the study
Key exclusion criteria (7 listed)
- Presence of a severe neurological disorder other than epilepsy
- Presence of a serious psychiatric disorder
- Advanced cognitive impairment or any condition preventing effective communication
- Unable to attend the educational sessions regularly
- Major change in the treatment protocol during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nurse-Led Stigma-Reduction-Based Epilepsy EducationParticipants in the intervention group will receive a structured nurse-led epilepsy education program focused on reducing stigma and supporting disease disclosure and self-management. The program will consist of four weekly sessions lasting approximately 45-60 minutes each. The sessions will address epilepsy-related knowledge and misconceptions, stigma and internalized stigma, concealment and disclosure of epilepsy, communication, medication adherence, seizure triggers, stress management, seizure diary use, and individualized self-management planning. | Behavioural | Experimental groups |
Primary outcome
Change in Epilepsy-Related Stigma
Time frame: Baseline and immediately after completion of the 4-week intervention
Epilepsy-related stigma will be assessed using the Epilepsy Stigma Scale. Total scores range from 25 to 100, with higher scores indicating greater epilepsy-related stigma (a worse outcome).
Change in Concealment of Epilepsy
Time frame: Baseline and immediately after completion of the 4-week intervention
Concealment of epilepsy will be assessed using the Concealment of Epilepsy Scale. Total scores range from 15 to 75, with higher scores indicating greater concealment of epilepsy (a worse outcome).
Change in Epilepsy Self-Management
Time frame: Baseline and immediately after completion of the 4-week intervention
Epilepsy self-management will be assessed using the Epilepsy Self-Management Scale. Total scores range from 38 to 190, with higher scores indicating more frequent use of epilepsy self-management behaviors (a better outcome).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nurse-Led Stigma-Reduction-Based Epilepsy Education in people with Epilepsy, run by Muş Alparslan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cihat Demirel, PhD (+905536186477, cihatdemirel34@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Epilepsy-Related Stigma (time frame: Baseline and immediately after completion of the 4-week intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.